Fisetin, a dietary bioflavonoid, reverses acquired cisplatin-resistance of lung adenocarcinoma cells through MAPK/Survivin/Caspase pathway

American Journal of Translational Research

Volumn 7, Issue 10, 2015, Pages 2045-2052

  Zhuo, Wenlei ^a   Zhang, Liang ^a   Zhu, Yi ^b   Zhu, Bo ^a   Chen, Zhengtang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

Cisplatin; Fisetin; MAPK signaling pathway; NSCLC A549 cells; Resistance

Indexed keywords

CASPASE 3; CASPASE 8; CISPLATIN; CYTOCHROME C; FISETIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER THERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LUNG ADENOCARCINOMA; MTT ASSAY; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84947781429     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Peng B, Wang YH, Liu YM and Ma LX. Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis. Int J Clin Exp Med 2015; 8: 3098-3106.
2. Feng PH, Yu CT, Wu CY, Lee MJ, Lee WH, Wang LS, Lin SM, Fu JF, Lee KY and Yen TH. Tumorassociated macrophages in stage IIIA pN2 non-small cell lung cancer after neoadjuvant chemotherapy and surgery. Am J Transl Res 2014; 6: 593-603.
3. Artal Cortes A, Calera Urquizu L and Hernando Cubero J. Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art. Transl Lung Cancer Res 2015; 4: 191-197.
4. Lee HY, Mohammed KA, Goldberg EP, Kaye F and Nasreen N. Cisplatin loaded albumin mesospheres for lung cancer treatment. Am J Cancer Res 2015; 5: 603-615.
5. Rose MC, Kostyanovskaya E and Huang RS. Pharmacogenomics of cisplatin sensitivity in non-small cell lung cancer. Genomics Proteomics Bioinformatics 2014; 12: 198-209.
6. Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 2014; 5: e1257.
7. Khan N, Syed DN, Ahmad N and Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal 2013; 19: 151-162.
8. Chen CM, Hsieh YH, Hwang JM, Jan HJ, Hsieh SC, Lin SH and Lai CY. Fisetin suppresses ADAM9 expression and inhibits invasion of glioma cancer cells through increased phosphorylation of ERK1/2. Tumour Biol 2015; 36: 3407-3415.
9. Chen Y, Wu Q, Song L, He T, Li Y, Li L, Su W, Liu L, Qian Z and Gong C. Polymeric micelles encapsulating fisetin improve the therapeutic effect in colon cancer. ACS Appl Mater Interfaces 2015; 7: 534-542.
10. Kang KA, Piao MJ and Hyun JW. Fisetin induces apoptosis in human nonsmall lung cancer cells via a mitochondria-mediated pathway. In Vitro Cell Dev Biol Anim 2015; 51: 300-309.
11. Syed DN, Lall RK, Chamcheu JC, Haidar O and Mukhtar H. Involvement of ER stress and activation of apoptotic pathways in fisetin induced cytotoxicity in human melanoma. Arch Biochem Biophys 2014; 563: 108-117.
12. Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, Syed DN, Siddiqui IA, Chiu SY and Mukhtar H. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget 2014; 5: 2462-2474.
13. Li R, Zhao Y, Chen J, Shao S and Zhang X. Fisetin inhibits migration, invasion and epithelial-mesenchymal transition of LMP1-positive nasopharyngeal carcinoma cells. Mol Med Rep 2014; 9: 413-418.
14. Li J, Qu W, Cheng Y, Sun Y, Jiang Y, Zou T, Wang Z, Xu Y and Zhao H. The inhibitory effect of intravesical fisetin against bladder cancer by induction of p53 and down-regulation of NFkappa B pathways in a rat bladder carcinogenesis model. Basic Clin Pharmacol Toxicol 2014; 115: 321-329.
15. Chung SY, Sung MK, Kim NH, Jang JO, Go EJ and Lee HJ. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005; 28: 823-828.
16. Murtaza I, Adhami VM, Hafeez BB, Saleem M and Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB. Int J Cancer 2009; 125: 2465-2473.
17. Ash D, Subramanian M, Surolia A and Shaha C. Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. Am J Cancer Res 2015; 5: 481-497.
18. Jung CH, Kim H, Ahn J, Jeon TI, Lee DH and Ha TY. Fisetin regulates obesity by targeting mTORC1 signaling. J Nutr Biochem 2013; 24: 1547-1554.
19. Syed DN, Adhami VM, Khan MI and Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem 2013; 13: 995-1001.
20. Suh Y, Afaq F, Johnson JJ and Mukhtar H. A plant flavonoid fisetin induces apoptosis in colon cancer cells by inhibition of COX2 and Wnt/ EGFR/NF-kappaB-signaling pathways. Carcinogenesis 2009; 30: 300-307.
21. de Sousa RR, Queiroz KC, Souza AC, Gurgueira SA, Augusto AC, Miranda MA, Peppelenbosch MP, Ferreira CV and Aoyama H. Phosphoprotein levels, MAPK activities and NFkappaB expression are affected by fisetin. J Enzyme Inhib Med Chem 2007; 22: 439-444.
22. Tripathi R, Samadder T, Gupta S, Surolia A and Shaha C. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther 2011; 10: 255-268.
23. Touil YS, Seguin J, Scherman D and Chabot GG. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol 2011; 68: 445-455.
24. Sahu BD, Kalvala AK, Koneru M, Mahesh Kumar J, Kuncha M, Rachamalla SS and Sistla R. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-kappaB activation and antioxidant defence. PLoS One 2014; 9: e105070.
25. Cetintas VB, Kucukaslan AS, Kosova B, Tetik A, Selvi N, Cok G, Gunduz C and Eroglu Z. Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines. Cell Biol Int 2012; 36: 261-265.
26. Geraets L, Haegens A, Brauers K, Haydock JA, Vernooy JH, Wouters EF, Bast A and Hageman GJ. Inhibition of LPS-induced pulmonary inflammation by specific flavonoids. Biochem Biophys Res Commun 2009; 382: 598-603.
27. Khan N, Afaq F, Syed DN and Mukhtar H. Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis 2008; 29: 1049-1056.
28. Park JH, Jang YJ, Choi YJ, Jang JW, Kim JH, Rho YK, Kim IJ, Kim HJ, Leem MJ and Lee ST. Fisetin inhibits matrix metalloproteinases and reduces tumor cell invasiveness and endothelial cell tube formation. Nutr Cancer 2013; 65: 1192-1199.
29. Pal HC, Sharma S, Strickland LR, Katiyar SK, Ballestas ME, Athar M, Elmets CA and Afaq F. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFkappaB signaling pathways. PLoS One 2014; 9: e86338.
30. Vandamme D, Herrero A, Al-Mulla F and Kolch W. Regulation of the MAPK pathway by raf kinase inhibitory protein. Crit Rev Oncog 2014; 19: 405-415.
31. Burotto M, Chiou VL, Lee JM and Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014; 120: 3446-3456.
32. Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA and Milella M. Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC. Curr Pharm Des 2014; 20: 3944-3957.
33. Gadgeel SM and Wozniak A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 2013; 14: 322-332.
34. Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK and Janne PA. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012; 2: 934-947.
35. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY. Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther 2013; 6: 1453-1462.
36. Wang HQ, Jin JJ and Wang J. Matrine induces mitochondrial apoptosis in cisplatinresistant non-small cell lung cancer cells via suppression of beta-catenin/survivin signaling. Oncol Rep 2015; 33: 2561-2566.
37. Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, Sun B, Zhang Q, Wang X, Jiang H, Krissansen GW, Qiao H and Sun X. Up-regulation of survivin by AKT and hypoxia-inducible factor 1alpha contributes to cisplatin resistance in gastric cancer. FEBS J 2014; 281: 115-128.